Loading stock…

JD Health International Inc. (6618) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

JD Health International Inc.

6618Market cap $14BPrice $4.5

Country🇨🇳China

SectorConsumer

IndustryConsumer Staples

Runs China's largest online pharmacy and health platform, delivering medicine and doctor consultations to hundreds of millions of users. Backed by JD's massive logistics network, it can get prescriptions to your door in under an hour in major cities.

In Bastion Portfolios?

52W Return-43%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+16%8

Revenue Forecast

Rev CAGR (1y)+22%8

Rev CAGR (3y)+15%8

Rev CAGR (5y)+13%8

Earnings Forecast

EPS Growth Y+1+32%9

EPS Growth Y+2+13%7

EPS Growth Y+3+19%8

Quality

Margins

EBIT Margin6%3

Net Income Margin8%5

Free Cash Flow Margin10%6

Debt

Net Debt/EBITDA-9.310

Efficiency

ROE10%5

ROA8%8

Earnings Stability1010

GEAR+VERY STRONG90

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)107

P/BV1.68

EV Multiples

EV/EBITDA Fwd410

EV/EBIT Fwd510

Yield

Free Cash Flow Yield8.5%9

Dividend Yieldna–

Momentum

Short term

1 month return-4%6

3 month return-5%5

YTD return-36%1

Mid term

Price vs 52wHigh49%1

1 year return-47%1

Long term

3 year return-8%2

5 year return-52%1

Risk Shield

Price Risk

Beta1.32

Volatility43%4

Free Cash Flow

Free Cash Flow Margin10%6

Free Cash Flow Yield8.5%9

Quality

ROCE8%5

Earnings Stability1010

Net Debt/EBITDA-9.310

02Growth

Is it actually growing, and how fast?

6618JD Health International

Revenue FY25$10.5B

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+22%8

Revenue, next 3Y, CAGR+15%8

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+32%9

EPS growth, FY27E+13%7

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 15%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 16%/yr over the last 3 years and is set to keep growing around 15%/yr.

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 19%/yr vs revenue 15%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

6618JD Health International

Total return Current−76.8%

Price return Current−76.8%

MOMENTUM RATING↗

VERY WEAK10 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-5%5

YTD return-36%1

MID & LONG-TERM▾SCORE

% of 52-week high49%1

1-year return-47%1

3-year return-8%2

5-year return-52%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.7% over three years and -52% over five), behind 80% of the market.

It's down 47% over the past year, now 51% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-36%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on JD Health. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

6618JD Health International

Revenue FY25$10.5B

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+22%8

Revenue, next 3Y, CAGR+15%8

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+32%9

EPS growth, FY27E+13%7

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 15%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 16%/yr over the last 3 years and is set to keep growing around 15%/yr.

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 19%/yr vs revenue 15%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

6618JD Health International

Total return Current−76.8%

Price return Current−76.8%

MOMENTUM RATING↗

VERY WEAK10 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-5%5

YTD return-36%1

MID & LONG-TERM▾SCORE

% of 52-week high49%1

1-year return-47%1

3-year return-8%2

5-year return-52%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.7% over three years and -52% over five), behind 80% of the market.

It's down 47% over the past year, now 51% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-36%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on JD Health. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community